

Die Leukapherese als immunologisches Ausgangsprodukt der CAR-T-Zelltherapie im Kontext zunehmender Indikationen und steigender Nachfrage

Literaturhinweise / Quellenangaben

1. Paul W. Hotz MT, Bastian von Tresckow. CAR-T-Zelltherapie bei diffusem großzelligen B-Zell-Lymphom: eine bahnbrechende Behandlungsoption. hämotherapie. 2024; Ausgabe 42/2024.
2. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45–56.
3. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiecek J, Go WY. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531–2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10. PMID: 29226797; PMCID: PMC5882485.
4. Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294–308.
5. Munshi NC, Anderson LD, Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384(8):705–16.
6. San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023;389(4):335–47.
7. Fischbach F, Richter J, Pfeffer LK, Fehse B, Berger SC, Reinhardt S, et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. 2024;5(6):550–8 e2.
8. Muller F, Boeltz S, Knitza J, Aigner M, Volkl S, Kharboul S, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023;401(10379):815–8.
9. Mackensen A, Muller F, Mougiakakos D, Boltz S, Wilhelm A, Aigner M, et al. Author Correction: Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2023;29(11):2956.
10. Hegde M, Navai S, DeRenzo C, Joseph SK, Sanber K, Wu M, et al. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024;5(6):880–94.
11. Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, et al. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med. 2023;388(14):1284–95.
12. Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016;375(26):2561–9.

13. Braun DA, Moranzoni G, Chea V, McGregor BA, Blass E, Tu CR, et al. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. *Nature*. 2025;639(8054):474–82.
14. Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. *Nature*. 2023;614(7949):635–48.
15. Odendahl M B, Eitler J, Tonn T. Chimäre Antigenrezeptor-exprimierende T-Zellen für die Krebsimmuntherapie. *Hämotherapie*. 2020;34.
16. Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, et al. Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies. *Front Immunol*. 2019;10:2664.
17. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. *N Engl J Med*. 2020;382(14):1331–42.
18. Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, et al. Long-Term (≥ 5 -Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. *J Clin Oncol*. 2025;JCO2500760.
19. Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study. *Lancet*. 2023;402(10402):641–54.
20. Chiesa R, Georgiadis C, Syed F, Zhan H, Etuk A, Gkazi SA, et al. Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia. *N Engl J Med*. 2023;389(10):899–910.
21. Hagen M, Bucci L, Boltz S, Nothling DM, Rothe T, Anoshkin K, et al. BCMA-Targeted T-Cell-Engager Therapy for Autoimmune Disease. *N Engl J Med*. 2024;391(9):867–9.
22. Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). *Hämatologica*. 2020;105(2):297–316.
23. Worel N, Holbro A, Vrielink H, Ootjers C, Le Poole K, Beer-Wekking I, et al. A guide to the collection of T-cells by apheresis for ATMP manufacturing—recommendations of the GoCART coalition apheresis working group. *Bone Marrow Transplant*. 2023;58(7):742–8.
24. Worel N, Mooyaart JE, Hoogenboom JD, Daskalakis M, Tudesq JJ, Ram R, et al. CAR-T cell manufacturing failures and out-of-specification products in the real-world setting: A survey from the EBMT cellular therapy and immunobiology working party. *Bone Marrow Transplant*. 2025.
25. Iacoboni G, Navarro V, Martin-Lopez AA, Rejeski K, Kwon M, Jalowiec KA, et al. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy. *J Clin Oncol*. 2024;42(2):205–17.
26. St-Pierre F, Bhatta S, Doukas PG, Jenkin M, Annunzio K, Rojek AE, et al. Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma—Results from a multicenter cohort study. *Blood Cancer J*. 2025;15(1):110.
27. Das RK, Vernau L, Grupp SA, Barrett DM. Naive T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers. *Cancer Discov*. 2019;9(4):492–9.
28. Singh N, Perazzelli J, Grupp SA, Barrett DM. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. *Sci Transl Med*. 2016;8(320):320ra3.
29. Li M, Yao D, Zeng X, Kasakovski D, Zhang Y, Chen S, et al. Age related human T cell subset evolution and senescence. *Immun Ageing*. 2019;16:24.

30. Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E, et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. *J Hematol Oncol*. 2016;9(1):116.
31. Shenghui Z, Yixiang H, Jianbo W, Kang Y, Laixi B, Yan Z, et al. Elevated frequencies of CD4(+) CD25(+) CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. *Int J Cancer*. 2011;129(6):1373–81.
32. Le Dieu R, Taussig DC, Ramsay AG, Mitter R, Miraki-Moud F, Fatah R, et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. *Blood*. 2009;114(18):3909–16.
33. Johnson PC JC, Yi A, Gaballa MR, Horick N, Rabideau DJ, Lindell K, DePinho GD, El-Jawahri AR, Frigault MJ. Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy. *J Immunother Cancer*. 2022(2022;10:e004567).
34. Wada F, Jo T, Arai Y, Kitawaki T, Mizumoto C, Kanda J, et al. T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy. *Sci Rep*. 2022;12(1):18696.
35. Chen GM, Chen C, Das RK, Gao P, Chen CH, Bandyopadhyay S, et al. Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy. *Cancer Discov*. 2021;11(9):2186–99.
36. Wilson TL, Kim H, Chou CH, Langfitt D, Mettelman RC, Minervina AA, et al. Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages. *Cancer Discov*. 2022;12(9):2098–119.
37. Wang Y, Tong C, Lu Y, Wu Z, Guo Y, Liu Y, et al. Characteristics of premanufacture CD8(+)T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma. *Signal Transduct Target Ther*. 2023;8(1):409.
38. Bai Z, Woodhouse S, Zhao Z, Arya R, Govek K, Kim D, et al. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. *Sci Adv*. 2022;8(23):eabj2820.
39. Bai Z, Feng B, McClory SE, de Oliveira BC, Diorio C, Gregoire C, et al. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. *Nature*. 2024;634(8034):702–11.
40. Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. *Nat Med*. 2022;28(9):1848–59.
41. Rade M, Grieb N, Weiss R, Sia J, Fischer L, Born P, et al. Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma. *Nat Cancer*. 2024;5(9):1318–33.
42. Zandaki D, Selukar S, Bi Y, Li Y, Zinsky M, Bonifant CL, et al. EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy. *Blood Adv*. 2025;9(2):270–9.
43. Korell F, Penack O, Mattie M, Schreck N, Benner A, Krzykalla J, et al. EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Cohort Study. *Front Immunol*. 2022;13:877477.
44. Frenking JH, Zhou X, Wagner V, Hielscher T, Kauer J, Mai EK, et al. EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma. *J Immunother Cancer*. 2024;12(10).
45. Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. *Blood*. 2021;138(24):2499–513.
46. Rejeski K, Perez A, Iacoboni G, Penack O, Bucklein V, Jentzsch L, et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. *J Immunother Cancer*. 2022;10(5).

47. Gazeau N, Beauvais D, Tilmont R, Srour M, Ferrant E, Safar V, et al. Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time? *Leukemia*. 2025;39(7):1714–22.
48. Hamilton MP, Miklos DB, Alizadeh AA. Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. Reply. *N Engl J Med*. 2024;391(9):870–1.
49. Dulery R, Guiraud V, Choquet S, Thieblemont C, Bachy E, Barete S, et al. T cell malignancies after CAR T cell therapy in the DESCAR-T registry. *Nat Med*. 2025;31(4):1130–3.
50. Elsallab M, Ellithi M, Lunning MA, D'Angelo C, Ma J, Perales MA, et al. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System. *Blood*. 2024;143(20):2099–105.
51. Kobbe G, Bruggemann M, Baermann BN, Wiegand L, Trautmann H, Yousefian S, et al. Aggressive Lymphoma after CD19 CAR T-Cell Therapy. *N Engl J Med*. 2024;391(13):1217–26.
52. Braun T, Rade M, Merz M, Klepzig H, Grosse F, Fandrei D, et al. Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody. *Nat Med*. 2025;31(4):1145–53.